Lilly Demo
Patient Journey Demonstration

Meet Maia

A representative patient navigating the path to Zepbound® using Teleport Health.

Maia Hernandez
47 • Austin, TX • Mother of two
BMI 34Prediabetes (A1c 6.2%)HypertensionFamily history of T2D
✓Medical records connected  · 211 records via MyChart
Before Teleport
✕Understand coverage and costs
✕Complete prior authorization
✕Find medication availability
✕Coordinate care
With Teleport
✓Connect medical records securely
✓Find out if treatment is right for you
✓Navigate insurance requirements
✓Get your medication to a pharmacy near you
✓Support treatment initiation
✓Stay engaged through treatment

Follow Maia's treatment journey and see how Teleport supports patients — from qualifying and getting covered to starting treatment and staying on track.

Maia is a fictional persona. Zepbound® is a registered trademark of Eli Lilly and Company.

Morning, Maia 👋

FindingsSee all
Insurance renewal due Mar 30

Your renewal paperwork is ready. It shows your 15% weight loss and on-time doses. Teleport can submit it today.

Review & submit →
Dose decision ahead

Dr. Rao suggested stepping up to 10 mg. Your visit guide compares moving up vs. staying at your dose — and how to handle side effects either way.

Open visit brief →
ActionsSee all
Insurance renewalZepbound® coverageDrafted
Next: Review and senddue Mar 30
Pharmacy refillZepbound® 7.5 mg · titration step · pen #16Processing
Next: Savings card applied at fillships Fri
Visit prepDr. Rao · telehealth Mar 24, 3:00 PMReady
Next: Your visit guide is ready — 3 questions to ask1–2 min read
Quick accessSee all
Care team
Health records
Medications
Appointments
Coverage
Injection guide
Maia's GLP-1 story
choose to begin ▶

Maia's GLP-1 journey

9 steps · your choices fill this in
Maia Hernandez's Twin
92%
Open Maia's health records
211 FHIR resources · twin 92% complete
Health records
Maia Hernandez
47y · female  # W2738461902
4
CONDITIONS
2
MEDICATIONS
2
ALLERGIES
Clinical Narrative

47-year-old with obesity and prediabetes, 4 months into tirzepatide (currently at 7.5 mg titration step; maintenance target 10 mg). Down 30 lb (BMI 34→29), A1c 6.2→5.6%, LDL 145→128 (with lifestyle changes).

MOST PRESSING NEXT ACTION
GLP-1 Re-Authorization due Mar 30
Illustrative · internal review only · not promotional. Indication, ISI, and boxed warning intentionally omitted.